



TOPOTARGET AND CARDINAL HEALTH REACH PURCHASE AND DISTRIBUTION SERVICES AGREEMENT

*Totect[®] for the Treatment of Anthracycline Extravasation
Now Available Through Cardinal Health Specialty Pharmaceutical Distribution*

ROCKAWAY, N.J., September 17, 2008 – TopoTarget USA, Inc., the U.S. subsidiary of TopoTarget A/S, a Denmark-based biotechnology firm specializing in cancer treatment, announced today that it has reached agreement with Cardinal Health for the wholesale purchase and distribution of Totect[®] (dexrazoxane hydrochloride for injection). Under the terms of the agreement, Cardinal Health will serve as an authorized distributor of Totect[®], the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for the treatment of extravasation from intravenous anthracycline chemotherapy, the accidental leakage of chemotherapy drugs into surrounding tissue.

The agreement effectively expands institutional access to Totect[®], thereby allowing greater numbers of health professionals to initiate timely treatment of anthracycline extravasation, a medical emergency that can result in serious, debilitating tissue injury.

“The wholesale purchase and distribution agreement with Cardinal Health is an important milestone for TopoTarget, as it roughly doubles the number of providers in the U.S. who are able to access Totect[®],” commented John L. Parsons, Jr. President of TopoTarget USA, Inc. “With its broad reach and long-established institutional relationships throughout the country, Cardinal Health is an ideal partner for TopoTarget as we seek to make Totect[®] more widely available to hospitals and cancer treatment centers.”

About Totect[®]

Totect[®] received approval, under an orphan drug designation, from the FDA on September 6, 2007. In addition to Cardinal Health, the product is available to cancer treatment facilities throughout the U.S. through ASD Healthcare and Oncology Supply, both AmeriSource Bergen companies. An estimated 3,600 oncology centers in the U.S. could benefit from having a Totect[®] kit available in the event of an anthracycline extravasation. TopoTarget A/S, the parent company, distributes this treatment in Europe under the brand name Savene[®].

In addition to its orphan drug exclusivity, Totect[®] is a patent-protected product. For general information on Totect[®], please visit www.totect.com or call (866) 914-2922. To order Totect[®], please call (800) 746-6273. Full prescribing information, including clinical trial information, safety, dosing, drug interactions and contraindications, is available at www.totect.com.

To purchase Totect[®] through your Cardinal Health Specialty Pharmaceuticals distributor, please call (866) 677-4844.

Contraindications: None known Warnings: Pregnancy Category D Precautions: Totect[®] is a cytotoxic drug. When administered to patients receiving anthracycline containing cytotoxic therapy, additive cytotoxicity may occur. Treatment with Totect[®] is associated with leukopenia, neutropenia, and thrombocytopenia. Hematological monitoring should be performed. Reversible elevations of liver enzymes may occur with dexrazoxane. Patients with Moderate or Severe Renal Insufficiency: Greater exposure to dexrazoxane may occur in patients with compromised renal function. The Totect[®] dose should be reduced by 50% in patients with creatinine clearance values <40mL/min. Dimethylsulfoxide (DMSO) should not be used in patients who are receiving dexrazoxane to treat anthracycline-induced extravasation. Laboratory Tests: Blood counts and liver enzymes should be monitored. Adverse Reactions: Dexrazoxane has been studied previously as a cytotoxic agent. Adverse reactions of nausea/vomiting, diarrhea, stomatitis, bone marrow suppression (neutropenia, thrombocytopenia), altered liver function (increased AST/ALT), and infusion site burning have been observed. These adverse reactions have been reversible.

About TopoTarget

TopoTarget (OMX: TOPO) is an international biotech company headquartered in Denmark, dedicated to finding “Answers for Cancer” and developing improved cancer therapies. The company is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors). TopoTarget has a broad clinical pipeline with eight products in development, including belinostat which has shown proof of concept as monotherapy in treating haematological malignancies and positive results in solid tumours where it can be used in combination with full doses of chemotherapy. The company's first marketed product Savene[®]/Totect[®] was approved by EMEA in 2006 and the FDA in 2007 and is marketed by TopoTarget's own sales force in Europe and the U.S. For more information, please refer to www.topotarget.com.

TopoTarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forwardlooking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forwardlooking statements as a result of various factors, including, but not limited to, the following: the risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability exposure. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

###